Effects of maternal psychotropic drug dosage on birth outcomes

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2013, Pages 13-18

  Michielsen, Laura A ^a   van der Heijden, Frank M M A ^a   Janssen, Paddy K C ^b   Kuijpers, Harold J H ^a  

^a VINCENT VAN GOGH INSTITUTE FOR PSYCHIATRY   (Netherlands)

^b VIECURI MEDICAL CENTER   (Netherlands)

Author keywords

Birth outcomes; Dosage; Pregnancy; Psychotropic medication

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CENTRAL STIMULANT AGENT; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; HYPNOTIC AGENT; LITHIUM; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; PAROXETINE; PIPAMPERONE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; VALPROIC ACID; VENLAFAXINE;

ADULT; ANXIETY DISORDER; APGAR SCORE; ARTICLE; BIRTH WEIGHT; COMPARATIVE STUDY; DEPRESSION; DOSE RESPONSE; DRUG DOSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; INTERMEDIATE DOSE; IRON THERAPY; LOW BIRTH WEIGHT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MOOD DISORDER; PERSONALITY DISORDER; PREGNANCY OUTCOME; PREMATURE LABOR; PSYCHOSIS; SMALL FOR DATE INFANT; STILLBIRTH;

EID: 84890303567     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S53430     Document Type: Article

References (29)

1. Vesga-López O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008;65(7):805-815.
2. El Marroun H, Jaddoe VW, Hudziak JJ, et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry. 2012;69(7):706-714.
3. Davalos D, Yadon C, Tregellas H. Untreated prenatal maternal depression and the potential risks to offspring: a review. Arch Womens Ment Health. 2012;15(1):1-14.
4. Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry. 2011;24(1):34-40.
5. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med. 2009;163(10):949-954.
6. Hayes RM, Wu P, Shelton RC, et al. Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. Am J Obstet Gynecol. 2012;207(1):49.
7. Lewis AJ, Galbally M, Opie G, Buist A. Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust N Z J Psychiatry. 2010;44(5):482-487.
8. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63(8):898-906.
9. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68(11):1104-1112.
10. Salisbury AL, Wisner KL, Pearlstein T, Battle CL, Stroud L, Lester BM. Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment. Depress Anxiety. 2011;28(11):1008-1019.
11. Esposito M, Gallaj B, Parisi L, et al. Visuomotor competencies and primary monosymptomatic nocturnal enuresis in prepubertal aged children. Neuropsychiatr Dis Treat. 2013;9:921-926.
12. Esposito M, Verrotti A, Gimigliano F, et al. Motor coordination impairment and migraine in children: a new comorbidity? Eur J Pediatr. 2012; 171(11):1599-1604.
13. de Vries NK, van der Veere CN, Reijneveld SA, Bos AF. Early neurological outcome of young infants exposed to selective serotonin reuptake inhibitors during pregnancy: results from the observational SMOK study. PLoS One. 2013;8(5):e64654.
14. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ. 2013;346:f2059.
15. Nordeng H, van Gelder MM, Spigset O, Koren G, Einarson A, Eberhard-Gran M. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study. J Clin Psychopharmacol. 2012;32(2): 186-194.
16. Wisner KL, Bogen DL, Sit D, et al. Does fetal exposure to SSRIs or maternal depression impact infant growth? Am J Psychiatry. 2013;170(5):485-493.
17. Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord. 2011;128(1-2):1-9.
18. Boden R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69(7):715-721.
19. Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry. 2007;164(8): 1206-1213.
20. Roca A, Garcia-Esteve L, Imaz ML, et al. Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose. J Affect Disord. 2011;135(1-3): 208-215.
21. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry. 2008;192(5):338-343.
22. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: The importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80(1):18-27.
23. Statistics Netherlands. Annual report on integration 2008. Available from: http://www.cbs.nl. Updated 2008. Accessed July 16, 2012.
24. WHO Collaborating Centre for Drug Statistics. ATC/DDD index 2012. Available from: http://www.whocc.no/atc_ddd_index/. Updated 2011. Accessed June 20, 2012.
25. Visser GH, Eilers PH, Elferink-Stinkens PM, Merkus HM, Wit JM. New Dutch reference curves for birthweight by gestational age. Early Hum Dev. 2009;85(12):737-744.
26. Dutch Society of Obstetrics and Gynaecology. SSRI-gebruik in de zwangerschap en tijdens de lactatie [Guideline for SSRI use in pregnancy and lactation]. Available from: http://nvog-documenten.nl/index.php?pagina=/richtlijn/pagina.php&fSelectTG_62=75&fSelectedSub=62 &fSelectedParent=75. Updated 2012. Accessed January 8, 2013. Dutch.
27. Ehrenstein V, Pedersen L, Grijota M, Nielsen GL, Rothman KJ, Sørensen HT. Association of Apgar score at five minutes with long-term neurologic disability and cognitive function in a prevalence study of Danish conscripts. BMC Pregnancy Childbirth. 2009;9:14.
28. Waelput AJM. Hoe vaak komt vroeggeboorte voor en hoeveel kinderen sterven eraan? [The incidence of preterm birth and the related mortality rate]. Available from: http://www.nationaalkompas.nl. Updated 2011. Accessed July 19, 2012. Dutch.
29. Dutch statistics. Perinatale en zuigelingensterfte eenlingkinderen; geboortegewicht. [Perinatal and infant mortality in singleton children; birthweight]. Available from: http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=80215NED&D1=0-2,4-5,7,18-19,21-22&D2=a&D3=0,3,l&HDR=T &STB=G2,G1&VW=T. Updated 2011. Accessed July 19, 2012. Dutch.